The liver peptide hepcidin regulates iron absorption and recycling. Hemojuvelin (HJV) has a key role in hepcidin regulation, and its inactivation causes severe iron overload both in humans and in mice. Membrane HJV (m-HJV) acts as a coreceptor for bone morphogenetic proteins (BMPs), whereas soluble HJV (s-HJV) may down-regulate hepcidin in a competitive way interfering with BMP signaling. s-HJV is decreased by iron in vitro and increased by iron deficiency in vivo.
IntroductionThe liver peptide hepcidin is the key regulator of systemic iron homeostasis 1 since it determines the level of circulating iron controlling intestinal iron absorption and macrophage iron recycling. Hemojuvelin (HJV) is a recently recognized protein that plays a crucial role in the regulation of hepcidin. The HJV gene, encoding HJV, is the gene of 1q-linked juvenile hemochromatosis, a recessive disease that leads to severe iron overload of early onset (hemochromatosis type 2A, OMIM no. 602390). 2 Patients with mutated HJV as well as Hjv Ϫ/Ϫ mice 3,4 have low/absent hepcidin levels, indicating that HJV modulates hepcidin. HJV is expressed in liver, skeletal muscle, and heart 2 and belongs to the family of repulsive guidance molecules (RGMs), expressed mainly in the central nervous system. 5,6 As are the other RGM proteins, HJV is characterized by a signal peptide, a RGD motif, a partial von Willebrand factor type D domain, and a glycosilphosphatidylinositol (GPI)-anchor domain. 2 HJV undergoes a partial autocatalytic cleavage 7 to reach the plasma membrane (m-HJV) as a cleaved heterodimer. 8,9 Recently, it was shown that HJV is a coreceptor for bone morphogenetic proteins (BMPs) and that hepcidin regulation occurs via the BMP/SMAD pathway. 10,11 BMP2 and BMP4 signaling is dependent on diferric transferrin, thus establishing a link between HJV-BMP and iron. 12 HJV exists in 2 forms: a membrane-bound (m-HJV) and a soluble one (s-HJV), which in vitro reciprocally regulate hepcidin expression in response to opposite iron changes. 7 s-HJV is able to interfere with and to block the signaling of BMP2 and BMP4 both in vitro 12 and in vivo. 13 We have previously documented the relevance of m-HJV in the molecular pathogenesis of juvenile hemochromatosis, providing evidence that at least some of the mutants identified as causal in patients are less efficiently targeted to the plasma membrane, compared with the wild-type protein. 9 Generation of s-HJV appears to be a regulated process decreased by iron treatment and diferric transferrin. 7 During our previous study, we have confirmed that this regulation is maintained in mutants, strengthening that s-HJV, suppressed by iron overload, is not involved in the disease pathogenesis. 9 We have also suggested that s-HJV does not derive from shedding of m-HJV, since its release in the medium is observed even in mutants that barely reach the plasma membrane. The discrepancy between the presence of m-HJV and the production of s-HJV is also well exemplified by the efficient secretion of soluble forms from varian...